This is a multicenter, randomized, single-masked, active-controlled, parallel, Phase III pivotal study in China
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
154
1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days
1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Peking University First Hospital
Beijing, China
Change from baseline in anterior chamber cell (ACC) grade in the study eye at Day 14
Time frame: Day 14
The proportion of subjects with ACC grade of 0 in the study eye at Day 14
Time frame: Day 14
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.